The global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market growth is projected to reach US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Trends And Outlook 2025-31

The global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Biologics for the prevention of reproductive and respiratory syndrome in pigs The growth and development of the swine industry, especially in regions with high pork consumption, has boosted the demand for vaccines for swine. As hog production expands to meet the growing demand for pork products, the need for effective disease prevention measures, including vaccination, becomes more important, driving the market for swine vaccines. Infinity Market Research newest research report, the ?Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Industry Forecast? looks at past sales and reviews total world Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales in 2024, providing a comprehensive analysis by region and market sector of projected Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales for 2025 through 2031. With Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live industry. This Insight Report provides a comprehensive analysis of the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live. This report presents a comprehensive overview, market shares, and growth opportunities of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; TJM-F92 Strain &nbsp;&nbsp;&nbsp; GDr180 Strain &nbsp;&nbsp;&nbsp; JXA1-R Strain &nbsp;&nbsp;&nbsp; Other Segmentation by Application: &nbsp;&nbsp;&nbsp; Farms &nbsp;&nbsp;&nbsp; Individual This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Yongshun Creatures &nbsp;&nbsp;&nbsp; Keqian Biology &nbsp;&nbsp;&nbsp; Boehringer Ingelheim &nbsp;&nbsp;&nbsp; Sinovet &nbsp;&nbsp;&nbsp; Elanco &nbsp;&nbsp;&nbsp; MSD &nbsp;&nbsp;&nbsp; Cahic &nbsp;&nbsp;&nbsp; Ringpu &nbsp;&nbsp;&nbsp; Baoling &nbsp;&nbsp;&nbsp; Jizhong &nbsp;&nbsp;&nbsp; Dahuanong &nbsp;&nbsp;&nbsp; Hayao &nbsp;&nbsp;&nbsp; Pulike Biology &nbsp;&nbsp;&nbsp; Tecon Key Questions Addressed in this Report What is the 10-year outlook for the global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market? What factors are driving Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live market opportunities vary by end market size? How does Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Type &nbsp;2.2.1 TJM-F92 Strain &nbsp;2.2.2 GDr180 Strain &nbsp;2.2.3 JXA1-R Strain &nbsp;2.2.4 Other &nbsp;2.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type &nbsp;2.3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Type (2020-2025) &nbsp;2.4 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Segment by Application &nbsp;2.4.1 Farms &nbsp;2.4.2 Individual &nbsp;2.5 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application &nbsp;2.5.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Breakdown Data by Company &nbsp;3.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Company (2020-2025) &nbsp;3.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sale Price by Company &nbsp;3.4 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Location Distribution &nbsp;3.4.2 Players Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Geographic Region &nbsp;4.1 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth &nbsp;4.4 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth &nbsp;4.5 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth &nbsp;4.6 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales Growth 5 Americas &nbsp;5.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country &nbsp;5.1.1 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2020-2025) &nbsp;5.1.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2020-2025) &nbsp;5.2 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2020-2025) &nbsp;5.3 Americas Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region &nbsp;6.1.1 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Region (2020-2025) &nbsp;6.1.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Region (2020-2025) &nbsp;6.2 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2020-2025) &nbsp;6.3 APAC Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country &nbsp;7.1.1 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2020-2025) &nbsp;7.1.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2020-2025) &nbsp;7.2 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2020-2025) &nbsp;7.3 Europe Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Country &nbsp;8.1.1 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live &nbsp;10.3 Manufacturing Process Analysis of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live &nbsp;10.4 Industry Chain Structure of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Distributors &nbsp;11.3 Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Customer 12 World Forecast Review for Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live by Geographic Region &nbsp;12.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Size Forecast by Region &nbsp;12.1.1 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecast by Region (2026-2031) &nbsp;12.1.2 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecast by Type (2026-2031) &nbsp;12.7 Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Yongshun Creatures &nbsp;13.1.1 Yongshun Creatures Company Information &nbsp;13.1.2 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.1.3 Yongshun Creatures Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Yongshun Creatures Main Business Overview &nbsp;13.1.5 Yongshun Creatures Latest Developments &nbsp;13.2 Keqian Biology &nbsp;13.2.1 Keqian Biology Company Information &nbsp;13.2.2 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.2.3 Keqian Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Keqian Biology Main Business Overview &nbsp;13.2.5 Keqian Biology Latest Developments &nbsp;13.3 Boehringer Ingelheim &nbsp;13.3.1 Boehringer Ingelheim Company Information &nbsp;13.3.2 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.3.3 Boehringer Ingelheim Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Boehringer Ingelheim Main Business Overview &nbsp;13.3.5 Boehringer Ingelheim Latest Developments &nbsp;13.4 Sinovet &nbsp;13.4.1 Sinovet Company Information &nbsp;13.4.2 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.4.3 Sinovet Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Sinovet Main Business Overview &nbsp;13.4.5 Sinovet Latest Developments &nbsp;13.5 Elanco &nbsp;13.5.1 Elanco Company Information &nbsp;13.5.2 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.5.3 Elanco Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Elanco Main Business Overview &nbsp;13.5.5 Elanco Latest Developments &nbsp;13.6 MSD &nbsp;13.6.1 MSD Company Information &nbsp;13.6.2 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.6.3 MSD Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 MSD Main Business Overview &nbsp;13.6.5 MSD Latest Developments &nbsp;13.7 Cahic &nbsp;13.7.1 Cahic Company Information &nbsp;13.7.2 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.7.3 Cahic Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Cahic Main Business Overview &nbsp;13.7.5 Cahic Latest Developments &nbsp;13.8 Ringpu &nbsp;13.8.1 Ringpu Company Information &nbsp;13.8.2 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.8.3 Ringpu Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Ringpu Main Business Overview &nbsp;13.8.5 Ringpu Latest Developments &nbsp;13.9 Baoling &nbsp;13.9.1 Baoling Company Information &nbsp;13.9.2 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.9.3 Baoling Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Baoling Main Business Overview &nbsp;13.9.5 Baoling Latest Developments &nbsp;13.10 Jizhong &nbsp;13.10.1 Jizhong Company Information &nbsp;13.10.2 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.10.3 Jizhong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Jizhong Main Business Overview &nbsp;13.10.5 Jizhong Latest Developments &nbsp;13.11 Dahuanong &nbsp;13.11.1 Dahuanong Company Information &nbsp;13.11.2 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.11.3 Dahuanong Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Dahuanong Main Business Overview &nbsp;13.11.5 Dahuanong Latest Developments &nbsp;13.12 Hayao &nbsp;13.12.1 Hayao Company Information &nbsp;13.12.2 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.12.3 Hayao Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Hayao Main Business Overview &nbsp;13.12.5 Hayao Latest Developments &nbsp;13.13 Pulike Biology &nbsp;13.13.1 Pulike Biology Company Information &nbsp;13.13.2 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.13.3 Pulike Biology Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Pulike Biology Main Business Overview &nbsp;13.13.5 Pulike Biology Latest Developments &nbsp;13.14 Tecon &nbsp;13.14.1 Tecon Company Information &nbsp;13.14.2 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Product Portfolios and Specifications &nbsp;13.14.3 Tecon Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 Tecon Main Business Overview &nbsp;13.14.5 Tecon Latest Developments 14 Research Findings and Conclusion

Report	Global Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Vaccine, Live Market Growth 2025-2031
Selected License	Single ID:LPI10619

Buyer Information

Order Summary